Audit: QRS - Danshen for Health & Longevity

Audit conducted on 17/08/2026 22:31 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	83
Failed	0
N/A	10
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	All protocol values, time-to-effect windows, gate items, benefit/risk tiers, biomarker targets and cadence trace to ER lines 385–397, 443, 351–359, 331–349, 163–231, 255–311, 473–495.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	No empty-state or hedged ER passage is carried into the QRS in altered form.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Pregnancy/breastfeeding, warfarin and the 2-week pre-surgical window all remain in the Contraindications gate at ER strength.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Gate items come only from ER Key Interactions & Contraindications; risks come only from Potential Risks & Side Effects; no modifying factor is repurposed.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	The QRS carries no PMIDs, citations, NCT identifiers or brand names at all.
1.6	The QRS does not introduce new attributions.	🟢	No author, institution, or manufacturer attribution appears anywhere in the sheet.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Measured, non-promotional register matching the ER’s Conclusion and Protocol sections.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Tiered benefits/risks and a concrete biomarker panel present the evidence without hype or discouragement.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Protocol cells state studied regimens rather than issuing instructions to an individual.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No imperative clinical directives; the footer disclaimer remains the template text.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	Wording throughout is descriptive (“Symptom endpoints in the angina trials”, “Detects occult blood loss”).
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronoun occurs anywhere in the rendered content.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms retained (hs-CRP, eGFR, Child-Pugh Class C) are the ER’s own biomarker and staging names, not avoidable jargon.
2.8	Information is presented in a concise and very compact manner	🟢	Gate and tier items are reduced to bare phrases; no sentence exceeds one clause of explanation.
2.9	It DOES NOT address the reader directly	🟢	Confirmed — no direct address in any span.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	The sheet leads with contraindications, interactions and a 10-marker monitoring panel, matching a risk-aware self-directed audience.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Baseline panel, twice-daily home blood pressure for 4 weeks, and 14-day pre-surgical washout assume an audience willing to do the work.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Content density and monitoring burden exceed a general-population format.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	At-A-Glance flags that bleeding is the main hazard and that product content varies by brand — the two facts that matter most to a self-directed user.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	“Anti-aging” does not appear; the title uses “Health & Longevity”.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	Body sections use formal terms (gastrointestinal intolerance, hypersensitivity, hepatic impairment); the plainer At-A-Glance wording is required by item 7.4 and mirrors the ER Conclusion.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All headings verified verbatim at lines 445, 491, 533, 564, 579, 602, 632, 636–638, 791; tier labels at 536, 540, 547, 554, 605, 609, 616, 623.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	70 named spans present with no gaps in any numbered series (action 1–3, time 1–3, marker 1–10, qualitative 1–6, plus all singleton spans).
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	The website="evidence_review", website="audit" and website="full_review" spans, the CSS block and the footer disclaimer are untouched.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No ER section that feeds the QRS is empty.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	“Standard crude-root dose”, “Standardised extract protocol” and “Time of day” match ER lines 385, 389, 397; all ten Monitoring row labels match the ER table at lines 477–486.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Marker names (INR, Platelet count, Haemoglobin, Blood pressure, hs-CRP, LDL-C, ALT, eGFR and urine albumin-to-creatinine ratio, HbA1c, Free digoxin) are carried verbatim.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji present; the ER’s ⚠️ Conflicted markers were correctly dropped.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section is condensed to bare phrases; the Monitoring table and Qualitative list carry the completeness required by items 14.2 and 15.2 without added prose.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Comment opens at line 2, immediately after the doctype at line 1.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- at line 3, closing --- at line 13; the preamble text sits on line 2.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment and not duplicated in head or body.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:04" is quoted, which is required because the value contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: danshen_2026-0825-2017_Opus_ER.md.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.7.02, matching this prompt’s version badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0817-2224.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” — single word, no version.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” — nickname plus version, no qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9 matches the file on disk: danshen_2026-0825-2017_Opus_QRS.html.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all nine keys; no stray whitespace or unnecessary quoting.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: “Danshen for Health & Longevity - Quick Reference Sheet”, matching ER canonical_topic with the ampersand encoded.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417: “Danshen for Health & Longevity”.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: 08/17/2026, correct reformat of 2026-0817-2224.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: “Opus 5”.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header contains only title and the template subline; the ER’s alternate-names line was correctly not carried over.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Compresses ER lines 519–523: uneven evidence base, angina add-on signal, secondary measures, bleeding hazard, cost and product variability.
7.2	[at_a_glance] is no longer than 60 words	🟢	59 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Each clause maps to a separate Conclusion sentence (ER lines 519, 521, 523).
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	Uses “chest pain”, “blood thickness”, “kidney measures”, “standard heart medicines” — no acronyms or clinical-register terms.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial name, year, or sample size appears.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No numeric effect estimate appears.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All eight items trace to the ER “Populations who should avoid Danshen” list at lines 353–359.
8.2	[stop_items] represent the Contraindications from the ER	🟢	Complete coverage of the ER avoid-list, with the anticoagulant and inherited-bleeding-disorder clause split into two gate items.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Eight <li> elements at lines 567–574.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	ER trailing clauses “— classical texts treat the root as blood-moving…” and “— the most advanced grade of liver failure” were both stripped.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Platelet threshold 100 × 10⁹/L, both 90-day windows, the 2-week pre-surgical window, systolic < 100 mmHg and Child-Pugh Class C are all retained.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation in this section.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER names seven avoid-populations, and the section is correctly populated rather than empty.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All eight items trace to the ER interaction bullets at lines 335–349.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	Warfarin and direct oral anticoagulants are correctly omitted, both being covered by the “Warfarin or another anticoagulant” contraindication.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Eight <li> elements at lines 582–592.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Every ER “— caution/monitor” clause and its mitigation text was stripped; items are bare drug-class names.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Named drug lists retained for antiplatelets, antihypertensives, CYP substrates, NSAIDs, bleeding-prone supplements and co-formulated herbs.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation in this section.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER names ten interactions, and the section is correctly populated.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells trace to ER Therapeutic Protocol bullets at lines 385, 389 and 397.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Crude-root reference dose, standardised extract dose, and dosing time-of-day are the three executable anchors in the ER Protocol section.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER provides twelve protocol bullets, so all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine spans carry ER-derived content (9–15 g daily; 1,000 mg twice daily; morning and evening with meals).

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Angina symptoms, blood pressure, and viscosity/inflammatory/kidney markers — the full content of ER line 443.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Angina (High tier) first, blood pressure (Medium) second, viscosity/kidney markers (Medium, surrogate endpoints) third.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	Three distinct time-to-effect aspects are present in the ER.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	2–4 weeks, 2–4 weeks and 8–12 weeks with ER-derived sublines (“Time taken to separate from control”).
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides time-to-effect data at line 443.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All eleven items map one-to-one onto the ER benefit headings at lines 165–231.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present at lines 535, 538, 545, 552.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each item is the ER heading reduced to sentence case; no magnitude, CI, or trial detail carried over.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any benefit item.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four tiers carry items in the ER.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All nine items map one-to-one onto the ER risk headings at lines 257–311.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present at lines 604, 607, 614, 621.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each item is the ER heading reduced to sentence case; the ⚠️ Conflicted markers and all magnitudes were dropped.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any risk item; the 6.40%/1.57%/0.79% figures were correctly omitted.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four tiers carry items in the ER.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Table and cadence trace to ER Monitoring Protocol & Defining Success at lines 473–486.
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All ten ER biomarkers present with matching targets and rationales: INR, Platelet count, Haemoglobin, Blood pressure, hs-CRP, LDL-C, ALT, eGFR/uACR, HbA1c, Free digoxin.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Lines 780–785 carry the full ER cadence: baseline panel, twice-daily home BP for 4 weeks, clotting and FBC at 4 weeks, full panel at 12 weeks then every 6–12 months.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	Items match the ER “Qualitative markers worth tracking” list at lines 490–495.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All six ER qualitative markers present verbatim in [qualitative_item_1] through [qualitative_item_6].

Issues 17/08/2026 22:31

Pass rate 100.00%. No issues found.